Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given a consensus rating of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $56.00.

AGIO has been the subject of several research reports. Scotiabank dropped their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company in a research report on Friday, May 2nd. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday.

Agios Pharmaceuticals Trading Down 2.6 %

AGIO opened at $27.32 on Friday. The company has a market cap of $1.58 billion, a P/E ratio of 2.41 and a beta of 0.77. The company’s 50 day moving average is $29.23 and its 200-day moving average is $37.27. Agios Pharmaceuticals has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The firm had revenue of $8.73 million for the quarter, compared to analysts’ expectations of $9.86 million. On average, equities analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Activity at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares of the company’s stock, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.93% of the stock is owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $49,290,000. Adage Capital Partners GP L.L.C. acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth $9,957,000. Paradigm Biocapital Advisors LP bought a new stake in Agios Pharmaceuticals in the fourth quarter valued at $9,084,000. Deutsche Bank AG increased its stake in Agios Pharmaceuticals by 39.7% in the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company’s stock valued at $30,732,000 after purchasing an additional 265,637 shares in the last quarter. Finally, Casdin Capital LLC bought a new position in shares of Agios Pharmaceuticals during the 4th quarter worth about $8,215,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.